MacroGenics
Rockville, Maryland, United States · Biopharma, Biotechnology, Health Care
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. They have a strong emphasis on creating novel and differentiated oncology product candidates.
Key facts
- Headquarters
- Rockville, Maryland, United States
- Employees
- 350
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (MGNX)
- Website
- macrogenics.com
- Company page
Recent activity at MacroGenics
- : SEC 8-K (8.01): On April 8, 2026, MacroGenics, Inc. announced via press release that the U.S. Food and Drug Administration has lifted the partial clinical hold on its Phase 2 LINNET study. This study involves lorigerlimab, an investigational bispecific DART® molecule aimed at treating patients with gynecologic cancers, thus allowing the continuation and potential expansion of the clinical trials for this drug. The removal of the hold is significant as it enables the company to proceed with patient recruitment and advancement of the study, which may have important implications for both clinical development and the company's stock performance.
- : MacroGenics Appoints Eric Risser as President and Chief Executive Officer
Leadership
- Eric Risser, Chief Executive Officer
Verified email and direct lines for MacroGenics’s decision-makers are on Fundz. See plans
Employee benefit plans
MacroGenics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
MacroGenics in the news
- MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement - GlobeNewswire (May 04, 2026)
- MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures - Yahoo Finance (Mar 09, 2026)
- MacroGenics to sell manufacturing business for $123M, will focus on R&D - The Business Journals (May 12, 2026)
- Bora Group to Acquire MacroGenics’ GMP Manufacturing Operations for $122.5M - pan african visions (May 12, 2026)
- Bora Group to acquire MacroGenics manufacturing for $122.5 million - vir.com.vn (May 13, 2026)
- Bora Group to acquire MacroGenics’ manufacturing operations and CDMO business - Manufacturing Chemist (May 13, 2026)
- MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals - GlobeNewswire (May 11, 2026)
- Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations - The Sun Malaysia (Jul 02, 2026)
Companies similar to MacroGenics
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- TerSera · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- AbbVie Inc. · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About MacroGenics: questions and answers
What does MacroGenics do?
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. They have a strong emphasis on creating novel and differentiated oncology product candidates.
Where is MacroGenics headquartered?
MacroGenics is headquartered in Rockville, Maryland, United States.
How many employees does MacroGenics have?
MacroGenics has about 350 employees.
Who leads MacroGenics?
Eric Risser is a Chief Executive Officer at MacroGenics.
What is the latest news on MacroGenics?
On Apr 08, 2026, SEC 8-K (8.01): On April 8, 2026, MacroGenics, Inc. announced via press release that the U.S. Food and Drug Administration has lifted the partial clinical hold on its Phase 2 LINNET study. This study involves lorigerlimab, an investigational bispecific DART® molecule aimed at treating patients with
Is MacroGenics a public company?
Yes. MacroGenics is publicly traded under the ticker MGNX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy